Poster Presentations: Wednesday, October 26, 2011 |

Correlation of Health Related Quality of Life Measures in Sarcoidosis Associated Pulmonary Hypertension FREE TO VIEW

Marc Judson, MD; Sooyeon Kwon, PhD; Kristin Highland, MD; James Donohue, MD; Robert Aris, MD; Nicole Craft, MS; Sharikia Burt, RN; Hubert Ford, MD
Chest. 2011;140(4_MeetingAbstracts):621A. doi:10.1378/chest.1114750
Text Size: A A A
Published online


PURPOSE: To analyze the correlation of 3 health related quality of life (HRQOL) measures: the Sarcoidosis Health Qestionnaire (SHQ), the Short Form-36 (SF-36), and the St. George Respiratory Questionnaire in patients enrolled in a treatment trial of ambrisentan for sarcoidosis associated pulmonary hypertension (SAPH).

METHODS: As part of a trial to examine the effect of ambrisentan 5 mg daily for one month followed by 10 mg daily for 5 additional months in 21 patients with SAPH (Sarc Vasc Diff Lung Dis, in press), 3 HRQOL measures, SHQ, SF-36, and SGRQ were measured at baseline and 8, 16, and 24 weeks of the trial. Correlations were made by comparing these 3 HRQOL measures in each patient at each time point. Pearson correlation (SAS version 9.2) was used for statistical analysis.

RESULTS: Data concerning these 3 HRQOL measurements were available for one patient at one time point on 57 occasions. If the data set were complete, there should have been 21 x 4 = 84 occasions. The reason for the incomplete data set included patient dropout as well as missing data from some of the HRQOL measurements. The correlations between global health composite t-score, SGRQ total score, SHQ total score, were highly significant among each other (all three pairs, p<0.0001; r ranged from 0.78 to 0.84) Dimension level correlations in SGRQ (symptom, acitivity, impact scores), SHQ (daily, physical, emotional), and SF-36 (mental, physical composite t-scores) also showed significant correlations (all p<0.02, in 51/56 r was greater than 0.50).

CONCLUSIONS: SGRQ, SF-36, and SHQ all correlated well with each other in patients with SAPH. In addition, the sub-scores of these HRQOL measures also correlated well with each other.

CLINICAL IMPLICATIONS: SGRQ, SF-36, and SHQ appear to be reasonable HRQOL measures for use in SAPH given their strong associations.

DISCLOSURE: Marc Judson: University grant monies: Gilead Sciences, Inc, University grant monies: Centocor, Consultant fee, speaker bureau, advisory committee, etc.: Centocor, Consultant fee, speaker bureau, advisory committee, etc.: Bohringer-Ingelheim, Consultant fee, speaker bureau, advisory committee, etc.: Pulmonary Reviews

Kristin Highland: Consultant fee, speaker bureau, advisory committee, etc.: Gilead Sciences, Inc, Consultant fee, speaker bureau, advisory committee, etc.: Actelion, Grant monies (from industry related sources): Gilead Sciences, Inc, Grant monies (from industry related sources): Actelion

James Donohue: Consultant fee, speaker bureau, advisory committee, etc.: Gilead Sciences, Inc

The following authors have nothing to disclose: Sooyeon Kwon, Robert Aris, Nicole Craft, Sharikia Burt, Hubert Ford

There is no FDA approved therapy for sarcoidosis associated pulmonary hypertension.

09:00 AM - 10:00 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543